Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HIPEx: Palbociclib plus endocrine therapy in high-risk ER-positive/HER2-negative early breast cancer
KCT0004553Phase 2Recruiting
- Sponsor
- Gencurix
- Start
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of palbociclib in Estrogen receptor-positive HER2-negative breast cancer (ER+/HER2-), sponsored by Gencurix. Started Apr 2020; status: recruiting.
02
Drugs
palbociclib
03
Conditions
Estrogen receptor-positive HER2-negative breast cancer (ER+/HER2-)
Beyond the preview
Go deeper on KCT0004553.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0004553.